Cost-effectiveness analysis of current varicose veins treatments

Objective: To analyze the effectiveness and cost effectiveness of technologies for treatment of varicose veins over 5 yearsdconservative care, surgery (high ligation and stripping), ultrasound-guided foam sclerotherapy (UGFS), endove Methods: A systematic review was updated and used to construct a Markov decision model. Outcomes were reintervention on the truncal vein, retreatment of residual varicosities and quality-adjusted life years (QALY) and costs over Results: UGFS has a significantly greater reintervention rate than other procedures; there is no significant difference between the other procedures. The cost per QALY of EVLA vs UGFS in our base-case model is 16,966 pound ($23,700) per QALY, which is considered cost effective in the UK. RFA, MOCA, and CAE have greater procedure costs than EVLA with no evidence of greater benefit for patients. Conclusions: EVLA is the most cost-effective therapeutic option, with RFA a close second, in adult patients requiring treatment in the upper leg for incompetence of the GSV. MOCA, UGFS, CAE, conservative care, and high ligation and stripping are not cost effective at current prices in the UK National Health Service. MOCA and CAE seem to be promising, but further evidence on the effectiveness, reinterventions, and health-related quality of life is needed, as well as how cost effectiveness may vary across settings and reimbursement systems. (J Vasc Surg Venous Lymphat Disord 2022;10:504-13.)